Avacta flags strong progress across oncology pipeline.

Avacta Therapeutics said on Monday that it had made strong progress across its oncology pipeline in the first half of 2026, including the start of clinical work for its second-generation preCISION drug candidate AVA6103.

Avacta Group
22 June 2026 09:44:29

Source: Sharecast

The AIM-traded clinical-stage biopharmaceutical company said the first patient was treated in March in the FOCUS-01 Phase 1 trial of AVA6103, following IND clearance in January.

It also reported updated Phase 1a and 1b data for AVA6000 showing encouraging early efficacy signals in salivary gland cancers, while regulators lifted the lifetime maximum dose limit after favourable cardiac safety findings.

Chief executive Christina Coughlin said the company’s data continued to validate its preCISION platform and reinforced its value for patients and potential partners.

Avacta said it had raised £41.5m over the past 18 months, extending its cash runway into early 2027, with initial AVA6103 clinical data expected in late H2 2026.

At 0922 BST, shares in Avacta Group were up 0.82% at 73.6p.

Reporting by Josh White for Sharecast.com.

See latest RNS on Investegate

N/A

ISIN: N/A

Exchange: N/A

Sell:

N/A

Buy:

N/A

Change:

Date:

Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.